Fusion Pharmaceuticals CEO John Valliant's 2020 pay jumps 399% to $7M
Fusion Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: April 27, 2021
Fusion Pharmaceuticals reported fiscal year 2020 executive compensation information on April 27, 2021.
In 2020, four executives at Fusion Pharmaceuticals received on average a compensation package of $3.2M, a 249% increase compared to previous year.
Average pay of disclosed executives at Fusion Pharmaceuticals
John Valliant, Chief Executive Officer, received $7M in total, which increased by 399% compared to 2019. 88% of Valliant's compensation, or $6.1M, was in option awards. Valliant also received $312K in non-equity incentive plan, $505K in salary, as well as $28K in other compensation.
James O'Leary, Chief Medical Officer, received a compensation package of $2.3M. 77% of the compensation package, or $1.8M, was in option awards.
Eric Burak, Chief Scientific Officer, earned $1.8M in 2020, a 277% increase compared to previous year.
John Crowley, Chief Financial Officer, received $1.6M in 2020, which increases by 88% compared to 2019.
Related executives
You may also like
Source: SEC filing on April 27, 2021.